Prurisol will increase the brand image (and value) of CTIX, provide substantial funding for additional Kevetrin trials, and solidify the brilliance of our leadership and potential of future compounds in the eyes of Big Pharma. This will all become a reality in Quarter 1 of 2013.

We believe that a new therapeutic bridging that gap could generate sales in excess of $1 billion annually, so we are naturally eager to see the effectiveness of Prurisol in human trials. The pharmaceutical industry bases the value of a new drug on market size and the therapeutic benefit to patients, so we consulted with industry leaders on the most expeditious manner to give them that information. A PoC trial in Europe was the answer. The trials early next year are another milestone for us to continue to build value for our shareholders."